CelLBxHealth PLC has signed a Master Services Agreement with a Swiss biotech firm to support a clinical study combining its circulating tumour cell (CTC) technology with radiopharmaceutical development. This collaboration aims to generate data for future cancer research and clinical applications, marking CelLBxHealth's entry into the growing radioligand therapy market. The company also targets £3-4 million revenue in 2027, more than doubling 2026 expectations, driven by new pharmaceutical contracts and increased business in Q3 2026.
CelLBxHealth's new contract with a Swiss biotech for clinical study provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 21, 2026 14:21 WIB: Out of 150 priced US health-sector stocks, 118 rose and 30 fell today. Notable movers include ISRG at USD 404.39 with a 1-day change of -7.67% and a typical hold time of 85 days, AMWL at USD 13.25 up 7.46%, and DYN at USD 16.34 up 7.29% with a typical hold time of 2 days and 100% buy order activity.
A webinar titled "Ready for AI?" scheduled for October 29, 2026, will discuss how artificial intelligence is reshaping public relations by changing how information is found, evaluated, and shared. Experts will share insights on maintaining message vi...
17a-4 LLC introduced DataParser Hub, an API that enables clients to integrate proprietary messaging and collaboration data into Microsoft 365 Purview and Copilot. This solution supports over 30 data types from platforms like Slack, Zoom, and Webex, a...
IBA has treated the first patient in the C-FLASH-01 clinical trial, the first human study testing ConformalFLASH® proton therapy. This trial, conducted at Penn Medicine with FDA approval, explores the feasibility of using ultra-high dose rate proton ...
IBA has treated the first patient in the C-FLASH-01 clinical trial, testing its ConformalFLASH® proton therapy for head and neck cancer re-irradiation. This trial, led by Penn Medicine and approved by the FDA, explores ultra-high dose rate proton the...
WISeQey Corp. completed its redomiciliation and began trading on Nasdaq and the SIX Swiss Exchange, marking a new phase focused on integrating its quantum cybersecurity, digital identity, and space IoT technologies. Its subsidiary WISeSat.Space also ...
